Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953121 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
A Phase 2 study of Malignant Glioma, sponsored by Annick Desjardins.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT00953121: Completed Phase 2 study of Malignant Glioma, sponsored by Annick Desjardins.
NCT00953121 is a Phase 2 study of Malignant Glioma that has completed, run by Annick Desjardins. The registered enrollment target is 104 participants, above the 89-participant average among 40 other Malignant Glioma trials with a reported enrollment target (17% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953121, a Phase 2 study of Malignant Glioma, has completed, sponsored by Annick Desjardins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
Conditions Studied
Interventions
- DRUG bevacizumab and CPT-11 and Carboplatin
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00953121
The ClinicalTrials.gov registry entry for NCT00953121 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 89-participant average among 40 other Malignant Glioma trials with a reported enrollment target (17% higher). The listed sponsor is Annick Desjardins, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 1 intervention - of which bevacizumab and CPT-11 and Carboplatin is the first listed.
NCT00953121 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00953121 about?
NCT00953121 is a clinical study titled "Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)". The purpose of this study is to determine whether Bevacizumab, CPT-11 and Carboplatin in combination are effective in the treatment of recurrent malignant glioma.
What is the current status of trial NCT00953121?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-09. Estimated completion is 2013-01.
What conditions does trial NCT00953121 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT00953121?
The interventions under investigation include: bevacizumab and CPT-11 and Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00953121?
This trial is sponsored by Annick Desjardins, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00953121 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
ACTIVE NOT RECRUITING · Phase 2
-
Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
ACTIVE NOT RECRUITING · Phase 2
-
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.